Therefore, further elucidating the full array of relaxin-3/RXFP3 network effects under normal and pathological conditions represents an important and promising research goal, which may eventually help meet the challenges and opportunities for improving the symptomatic treatment of sufferers of conditions such as anxiety and major depression, and the social and cognitive deficits in neurodevelopmental, and degenerative disorders, by restoring the required balance of excitatory/inhibitory transmission within the appropriate neural circuits. This evidence concerns the gene RLN3 and major depressive disorder.